Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 6Terminated 2Completed 2Withdrawn 1Unknown 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 117Myelodysplastic Syndromes 73Leukemia, Myelomonocytic, Chronic 34Leukemia 30Neoplasms 11Carcinoma, Non-Small-Cell Lung 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Myeloproliferative Disorders 8Lymphoma, Non-Hodgkin 8Lymphoma 8Leukemia, Myelomonocytic, Acute 8Congenital Abnormalities 8Recurrence 7Multiple Myeloma 7Lymphoma, Large B-Cell, Diffuse 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Leukemia, Monocytic, Acute 6Leukemia, Erythroblastic, Acute 6Primary Myelofibrosis 5Lung Neoplasms 5Leukemia, Megakaryoblastic, Acute 5Leukemia, Lymphocytic, Chronic, B-Cell 5Hodgkin Disease 5Hematologic Neoplasms 5Anemia, Refractory, with Excess of Blasts 5Prostatic Neoplasms 4Myelodysplastic-Myeloproliferative Diseases 4Melanoma 4Lymphoma, Follicular 4Pancreatic Neoplasms 3

Interventions

Cyclophosphamide 7blinatumomab 6Cytarabine 6fludarabine 5Mercaptopurine 5Methotrexate 4fludarabine phosphate 3Vincristine 3Rituximab 3Granulocyte Colony-Stimulating Factor 3Etoposide 3Drug Therapy 3Dexamethasone 3Daunorubicin 3Asparaginase 3Whole-Body Irradiation 2Vindesine 2Thioguanine 2Teniposide 2Stem Cell Transplantation 2Prednisolone 2N,N-dicyclohexyl-isoborneol-10-sulfonamide 2Interleukin-2 2Doxorubicin 2Cladribine 2Blood Specimen Collection 2Azacitidine 2tisagenlecleucel 1thymoglobulin 1sargramostim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Neoplasm, Residual × Azacitidine × Clear all
NCT04712942 2023-08-21

Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat

University of Leipzig

Phase 2 Completed
14 enrolled
Myeloid

Myelodysplastic Syndromes, Neoplasm, Residual

NCT01460498 2020-03-05

Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)

M.D. Anderson Cancer Center

Phase 1 Completed
3 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡